An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases.
Status:
Not yet recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical study is to evaluate multiple dose levels of povetacicept
(ALPN-303) in adults with immunoglobulin A (IgA) nephropathy, membranous nephropathy, or
lupus-related kidney disease (lupus nephritis) to determine if povetacicept is safe and
potentially beneficial in treating these diseases.
During the study treatment period, participants will receive povetacicept approximately every
4 weeks for 6 months, with the possibility of participating in a 6-month study treatment
extension period.